Carbamazepine and Soluplus® Solid Mixtures: A DSC Study
Carbamazepine is a common drug showing poor aqueous solubility and limited intestinal permeability when in its crystalline forms. Adding a surfactant such as Soluplus® can help improving both solubility and permeability by modulating its crystallinity. Differential Scanning Calorimetry can support studying the thermal behavior and crystallinity evolution of carbamazepine in solid mixtures with Soluplus®.
Carbamazepine (CBZ) is a well-known drug used for treating epilepsy and bipolar disorder. However, its usage is restricted by poor aqueous solubility. In fact, according to the Biopharmaceutics Classification System (BCS), carbamazepine is a class II drug. Class II drugs show low solubility and high intestinal permeability. In pharmaceutical formulations, the main goal is to increase the solubility of this kind of drugs. By adding Soluplus®, an amphiphilic polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, the solubility of carbamazepine can be fine-tuned [1]. Soluplus® forms a solid dispersion with carbamazepine, depressing the melting point of the latter and suppressing crystallinity after melting. Hereby, we aim to show how Differential Scanning Calorimetry (DSC) can support the study of changes in crystalline form of carbamazepine in combination with Soluplus® when forming a solid dispersion [2].
Get the document
To receive this document please enter your email below.
